Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study

Introduction Although hormonal-therapy is the preferred first-line treatment for hormone-responsive, HER2 negative metastatic breast cancer, no data from clinical trials support the choice between hormonal-therapy and chemotherapy. Methods Patients were divided into two groups according to the treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bighin, Claudia, Dozin, Beatrice, Poggio, Francesca, Ceppi, Marcello, Bruzzi, Paolo, D’Alonzo, Alessia, Levaggi, Alessia, Giraudi, Sara, Lambertini, Matteo, Miglietta, Loredana, Vaglica, Marina, Fontana, Vincenzo, Iacono, Giuseppina, Pronzato, Paolo, Mastro, Lucia Del
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546519/
https://www.ncbi.nlm.nih.gov/pubmed/28108743
http://dx.doi.org/10.18632/oncotarget.14735
_version_ 1783255566097842176
author Bighin, Claudia
Dozin, Beatrice
Poggio, Francesca
Ceppi, Marcello
Bruzzi, Paolo
D’Alonzo, Alessia
Levaggi, Alessia
Giraudi, Sara
Lambertini, Matteo
Miglietta, Loredana
Vaglica, Marina
Fontana, Vincenzo
Iacono, Giuseppina
Pronzato, Paolo
Mastro, Lucia Del
author_facet Bighin, Claudia
Dozin, Beatrice
Poggio, Francesca
Ceppi, Marcello
Bruzzi, Paolo
D’Alonzo, Alessia
Levaggi, Alessia
Giraudi, Sara
Lambertini, Matteo
Miglietta, Loredana
Vaglica, Marina
Fontana, Vincenzo
Iacono, Giuseppina
Pronzato, Paolo
Mastro, Lucia Del
author_sort Bighin, Claudia
collection PubMed
description Introduction Although hormonal-therapy is the preferred first-line treatment for hormone-responsive, HER2 negative metastatic breast cancer, no data from clinical trials support the choice between hormonal-therapy and chemotherapy. Methods Patients were divided into two groups according to the treatment: chemotherapy or hormonal-therapy. Outcomes in terms of clinical benefit and median overall survival (OS) were retrospectively evaluated in the two groups. To calculate the time spent in chemotherapy with respect to OS in the two groups, the proportion of patients in chemotherapy relative to those present in either group was computed at every day from the start of therapy. Results From 1999 to 2013, 119 patients received first-line hormonal-therapy (HT-first group) and 100 first-line chemotherapy (CT-first group). Patients in the CT-first group were younger and with poorer prognostic factors as compared to those in HT-first group. Clinical benefit (77 vs 81%) and median OS (50.7 vs 51.1 months) were similar in the two groups. Time spent in chemotherapy was significantly longer during the first 3 years in CT-first group (54-34%) as compared to the HT-first group (11-18%). This difference decreased after the third year and overall was 28% in the CT-first group and 18% in the HT-first group. Conclusions The sequence first-line chemotherapy followed by hormonal-therapy, as compared with the opposite sequence, is associated with a longer time of OS spent in chemotherapy. However, despite the poorer prognostic factors, patients in the CT-first group had a superimposable OS than those in the HT-first group.
format Online
Article
Text
id pubmed-5546519
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55465192017-08-23 Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study Bighin, Claudia Dozin, Beatrice Poggio, Francesca Ceppi, Marcello Bruzzi, Paolo D’Alonzo, Alessia Levaggi, Alessia Giraudi, Sara Lambertini, Matteo Miglietta, Loredana Vaglica, Marina Fontana, Vincenzo Iacono, Giuseppina Pronzato, Paolo Mastro, Lucia Del Oncotarget Clinical Research Paper Introduction Although hormonal-therapy is the preferred first-line treatment for hormone-responsive, HER2 negative metastatic breast cancer, no data from clinical trials support the choice between hormonal-therapy and chemotherapy. Methods Patients were divided into two groups according to the treatment: chemotherapy or hormonal-therapy. Outcomes in terms of clinical benefit and median overall survival (OS) were retrospectively evaluated in the two groups. To calculate the time spent in chemotherapy with respect to OS in the two groups, the proportion of patients in chemotherapy relative to those present in either group was computed at every day from the start of therapy. Results From 1999 to 2013, 119 patients received first-line hormonal-therapy (HT-first group) and 100 first-line chemotherapy (CT-first group). Patients in the CT-first group were younger and with poorer prognostic factors as compared to those in HT-first group. Clinical benefit (77 vs 81%) and median OS (50.7 vs 51.1 months) were similar in the two groups. Time spent in chemotherapy was significantly longer during the first 3 years in CT-first group (54-34%) as compared to the HT-first group (11-18%). This difference decreased after the third year and overall was 28% in the CT-first group and 18% in the HT-first group. Conclusions The sequence first-line chemotherapy followed by hormonal-therapy, as compared with the opposite sequence, is associated with a longer time of OS spent in chemotherapy. However, despite the poorer prognostic factors, patients in the CT-first group had a superimposable OS than those in the HT-first group. Impact Journals LLC 2017-01-18 /pmc/articles/PMC5546519/ /pubmed/28108743 http://dx.doi.org/10.18632/oncotarget.14735 Text en Copyright: © 2017 Bighin et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Clinical Research Paper
Bighin, Claudia
Dozin, Beatrice
Poggio, Francesca
Ceppi, Marcello
Bruzzi, Paolo
D’Alonzo, Alessia
Levaggi, Alessia
Giraudi, Sara
Lambertini, Matteo
Miglietta, Loredana
Vaglica, Marina
Fontana, Vincenzo
Iacono, Giuseppina
Pronzato, Paolo
Mastro, Lucia Del
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study
title Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study
title_full Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study
title_fullStr Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study
title_full_unstemmed Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study
title_short Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study
title_sort hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546519/
https://www.ncbi.nlm.nih.gov/pubmed/28108743
http://dx.doi.org/10.18632/oncotarget.14735
work_keys_str_mv AT bighinclaudia hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy
AT dozinbeatrice hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy
AT poggiofrancesca hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy
AT ceppimarcello hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy
AT bruzzipaolo hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy
AT dalonzoalessia hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy
AT levaggialessia hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy
AT giraudisara hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy
AT lambertinimatteo hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy
AT migliettaloredana hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy
AT vaglicamarina hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy
AT fontanavincenzo hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy
AT iaconogiuseppina hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy
AT pronzatopaolo hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy
AT mastroluciadel hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy